CliffBio
biologic

Pertzye

pancrelipase

Loss of exclusivityMay 2024projected — 12-year biologic exclusivity estimate
CompanyDigestive Care, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand namePertzye
Active ingredientpancrelipase
Strength8,000USP UNITS; 28,750USP UNITS; 30,250USP UNITS
Dosage formCapsule, Delayed Release
RouteOral
ModalityBiologic
FDA approvalMay 2012
Marketing statusRx

More from Digestive Care, Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Pertzye patent cliff — loss of exclusivity May 2024 | CliffBio